76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…
Zuellig Pharma, a leading healthcare solutions company in Asia, today announced the grand opening of its new state-of-the-art Clinical Trial…